Mutation in the Kinase Domain Alters the VEGFR2 Membrane Dynamics

被引:0
|
作者
Corsini, Michela [1 ,2 ]
Ravelli, Cosetta [1 ,3 ]
Grillo, Elisabetta [1 ,3 ]
Domenichini, Mattia [1 ]
Mitola, Stefania [1 ,2 ,3 ]
机构
[1] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy
[2] CN3 Sviluppo Terapia Genica & Farm Tecnol RNA, I-25123 Brescia, Italy
[3] CIB Consorzio Interuniv Biotecnol, I-25123 Brescia, Italy
关键词
TK receptors; FLIM/FRET; FRAP; molecular interaction; VEGFR2; RECEPTOR; PROTEIN; GROWTH; CYAN; FRET;
D O I
10.3390/cells13161346
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Recently, the substitution R1051Q in VEGFR2 has been described as a cancer-associated "gain of function" mutation. VEGFR2R1051Q phosphorylation is ligand-independent and enhances the activation of intracellular pathways and cell growth both in vitro and in vivo. In cancer, this mutation is found in heterozygosity, suggesting that an interaction between VEGFR2R1051Q and VEGFR2WT may occur and could explain, at least in part, how VEGFR2R1051Q acts to promote VEGFR2 signaling. Despite this, the biochemical/biophysical mechanism of the activation of VEGFR2R1051Q remains poorly understood. On these bases, the aim of our study is to address how VEGFR2R1051Q influences the biophysical behavior (dimerization and membrane dynamics) of the co-expressed VEGFR2WT. Methods: We employed quantitative FLIM/FRET and FRAP imaging techniques using CHO cells co-transfected with the two forms of VEGFR2 to mimic heterozygosity. Results: Membrane protein biotinylation reveals that VEGFR2WT is more exposed on the cell membrane with respect to VEGFR2R1051Q. The imaging analyses show the ability of VEGFR2WT to form heterodimers with VEGFR2R1051Q and this interaction alters its membrane dynamics. Indeed, when the co-expression of VEGFR2WT/VEGFR2R1051Q occurs, VEGFR2WT shows reduced lateral motility and a minor pool of mobile fraction. Conclusions: This study demonstrates that active VEGFR2R1051Q can affect the membrane behavior of the VEGFR2WT.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] KIF13B mediates VEGFR2 recycling to modulate vascular permeability
    Cho, Hyun-Dong
    Nhan, Nguyen Thi Thanh
    Zhou, Christopher
    Tu, Kayeman
    Nguyen, Tara
    Sarich, Nicolene A.
    Yamada, Kaori H.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (04)
  • [22] VEGFR2 regulates endothelial differentiation of colon cancer cells
    Liu, Zhiyong
    Qi, Lisha
    Li, Yixian
    Zhao, Xiulan
    Sun, Baocun
    BMC CANCER, 2017, 17
  • [23] Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis
    Hauer, Arnaud D.
    van Puijvelde, Gijs H. M.
    Peterse, Niels
    de Vos, Paula
    van Weel, Vincent
    van Wanrooij, Eva J. A.
    Biessen, Erik A. L.
    Quax, Paul H. A.
    Niethammer, Andreas G.
    Reisfeld, Ralph A.
    van Berkel, Theo J. C.
    Kuiper, Johan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (09) : 2050 - 2057
  • [24] Deltonin inhibits angiogenesis by regulating VEGFR2 and subsequent signaling pathways in endothelial cells
    Tong, Qingyi
    Zhao, Qingbing
    Qing, Yong
    Hu, Xiaojuan
    Jiang, Lei
    Wu, Xiaohua
    STEROIDS, 2015, 96 : 30 - 36
  • [25] The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates
    Jankowski, Vera
    Schulz, Anna
    Kretschmer, Axel
    Mischak, Harald
    Boehringer, Falko
    van der Giet, Markus
    Janke, Doreen
    Schuchardt, Mirjam
    Herwig, Ralf
    Zidek, Walter
    Jankowski, Joachim
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2013, 91 (09): : 1095 - 1107
  • [26] Microtubules Coordinate VEGFR2 Signaling and Sorting
    Czeisler, Catherine
    Mikawa, Takashi
    PLOS ONE, 2013, 8 (09):
  • [27] Combinatory action of VEGFR2 and MAP kinase pathways maintains endothelial-cell integrity
    Zhong, Hanbing
    Wang, Danyang
    Wang, Nan
    Rios, Yesenia
    Huang, Haigen
    Li, Song
    Wu, Xinrong
    Lin, Shuo
    CELL RESEARCH, 2011, 21 (07) : 1080 - 1087
  • [28] Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor
    Jang, Seong
    Strickland, Bill
    Finis, Lynda
    Kooijman, Jeffrey J.
    Melis, Janneke J. T. M.
    Zaman, Guido J. R.
    Van Tornout, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (06) : 491 - 499
  • [29] Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor
    Seong Jang
    Bill Strickland
    Lynda Finis
    Jeffrey J. Kooijman
    Janneke J. T. M. Melis
    Guido J. R. Zaman
    Jan Van Tornout
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 491 - 499
  • [30] Endoglin interacts with VEGFR2 to promote angiogenesis
    Tian, Hongyu
    Huang, Jennifer J.
    Golzio, Christelle
    Gao, Xia
    Hector-Greene, Melissa
    Katsanis, Nicholas
    Blobe, Gerard C.
    FASEB JOURNAL, 2018, 32 (06) : 2934 - 2949